CORONA Remedies Limited has informed the Exchange regarding Board meeting held on January 02, 2026.
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CORONA Remedies, a recently listed pharma company (IPO on Dec 15, 2025), reported its first set of quarterly results since listing. Q2 FY26 revenue stood at ₹361.13 Cr, up 15.1% YoY, while H1 FY26 revenue was ₹707.67 Cr, up 17.0% YoY. Profit after tax for Q2 was ₹52.32 Cr (+21.8% YoY) and H1 was ₹98.52 Cr (+35.1% YoY). EBITDA margin came in at 21.7% for Q2 and 20.9% for H1. The company also reported strong return ratios with RoE of 31.1% and RoCE of 49.7%. Operating cash flow for H1 was ₹113.44 Cr with OCF/EBITDA conversion of 76.5%. The auditor (Deloitte Haskins & Sells LLP) issued an unmodified limited review report.
This is a strong debut post-listing earnings print with double-digit revenue growth, robust 35% PAT growth in H1, healthy margins, and best-in-class return ratios. Positive read for shareholders as profitability scaled faster than revenue, indicating operating leverage. Management scheduled an earnings call on January 5, 2026 to provide further detail.